| Disease | AND IMPROVE QUALITY OF LIFE IN OTHERWISE HEALTHY SUBJECTS SUFFERING FROM DYSPEPSIA.
SECONDARY OUTCOME, WAS GREATER WITH THE HIGHER DOSAGE (P=0.03). HEALTH-REALTED QUALITY OF LIFE WAS SIGNIFICANTLY IMPROVED IN BOTH GROUPS COMAPRED WITH BASELINE. WE CONCLUDE THAT ALE SHOWS PROMISE TO AMELIORATE UPPER GASTRO-INTESTINAL SYMPTOMS
SIGNIFICANT REDUCTION OF ALL DYSPEPTIC SYMPTOMS, WITH AN AVERAGE REDUCTION OF 40% IN GLOBAL DYSPEPSIA SCORE. HOWEVER, THERE WERE NO DIFFERENCES IN THE PRIMARY OUTCOME MEASURES BETWEEN THE TWO GROUPS, ALTHOUGH RELIEF OF STATE ANXIETY, A
COMPLETED AT BASELINE AND AFTER 2 MONTHS OF TREATMENT WITH ALE, WHICH WAS RANDOMLY ALLOCATED TO VOLUNTEERS AS 320 OR 640 MG DAILY. OF THE 516 PARTICIPANTS, 454 COMPLETED THE STUDY. IN BOTH DOSAGE GROUPS, COMPARED WITH BASELINE, THERE WAS A
SYMPTOMS AND IMPROVEMENT OF QUALITY OF LIFE. THE STUDY WAS AN OPEN, DOSE-RENGING POSTAL STUDY. HEALTHY PATIENTS WITH SELF-REPORTED DYSPEPSIA WERE RECRUITED THROUGH THE MEDIA. THE NEPEAN DYSPEPSIA INDIEX AND STATE-TRAIT ANXIETY INVENTORY WERE
A POST-MARKETING STUDY INDICATED THAT HIGH DOSE OF STANDARDISED ANRTICHOKE LEAF EXTRACT (ALE) MAY REDUCE SYMPTOMS OF DYSPEPSIA. TO SUBSTANTIAL THESE FINDINGS, THIS STUDY INVESTIGATED THE EFFICACY OF A LOW-DOSE ALE ON AMELIORATION OF DYSPEPTIC |